Active — Not RecruitingNot Applicable

Liquid Biopsy Based NGS in Newly Diagnosed NSCLC

United States260 participantsStarted 2023-06-15

Plain-language summary

This study expands the application of an electronic health record (EHR) "nudge" used to prompt physicians' clinical practice to order molecular testing at the time of initial diagnosis for patients with specific types of advanced lung cancer. The primary goal is to have these test results available prior to starting treatment so that physicians can make molecularly-informed treatment decisions. The second goal is to better understand factors that contribute to whether or not the EHR-nudge implementation is successful.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Participants with a histological, or cytological diagnosis of metastatic non-squamous (mNSq) non-small cell lung cancer (NSCLC) who have not yet received systemic treatment for metastatic disease. * Participants must be seen at Lancaster General Health (LGH), Penn Presbyterian Medical Center (PPMC), Penn Medicine Cherry Hill (PMCH), Penn Medicine Princeton Health (PMPH), Penn Medicine Voorhees (PMV) or Penn Medicine Washington Township (PMWT) for mNSq NSCLC. Exclusion Criteria: * Participants with incomplete staging information. * Children, pregnant women, fetuses, neonates, or prisoners are not included in this research study.

What they're measuring

Availability of comprehensive molecular test results prior to first line therapy for patients with newly diagnosed mNSq NSCLC

Timeframe: Measured up to 6 weeks from initial diagnosis

Trial details

NCT IDNCT05853887

SponsorCharu Aggarwal

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-02-27

View on ClinicalTrials.gov More Non Small Cell Lung Cancer Metastatic trials